Litchfield Hills Research Weighs in on SLXN FY2026 Earnings

Silexion Therapeutics Corp (NASDAQ:SLXN) – Equities research analysts at Litchfield Hills Research boosted their FY2026 earnings estimates for shares of Silexion Therapeutics in a report issued on Monday, September 21st. Litchfield Hills Research analyst T. O’neill now anticipates that the company will earn ($4.70) per share for the year, up from their previous estimate of ($45.50). The consensus estimate for Silexion Therapeutics’ current full-year earnings is ($45.50) per share.

Several other brokerages have also recently weighed in on SLXN. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Silexion Therapeutics Trading Down 27.9%

Shares of Silexion Therapeutics stock opened at $0.39 on Wednesday. The stock has a 50 day moving average of $1.08 and a 200 day moving average of $5.36. Silexion Therapeutics has a 12 month low of $0.32 and a 12 month high of $42.60. The firm has a market cap of $2.18 million, a PE ratio of -0.01 and a beta of -0.36.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, beating the consensus estimate of ($21.20) by $16.03.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.